iVascular Launches Long-Lengths of Angiolite DES

February 9, 2021—iVascular announced the launch of new lengths for the Angiolite drug-eluting stent (DES) for the treatment of long lesions in the coronary arteries. The 44- and 49-mm lengths received the European CE Mark approval for the treatment of diffuse lesions.

According to the company, the new longer sizes can help reduce cost and increase procedural efficiency, thereby avoiding complications such as stents overlapping and less intervention time versus the use of more than one DES. With the Angiolite device, iVascular seeks to enhance the outcomes of complex procedures, such as long lesions. The Angiolite DES in 44- and 49-mm lengths are available for 2.50-, 2.75-, 3.0-, 3.5-, 4.0-mm diameters.

iVascular advised that the Angiolite DES is indicated for patients with symptomatic ischemic heart disease caused by de novo stenotic and restenotic lesions and patients with occlusive disease caused by acute myocardial infarction. The device is designed with alternating links to achieve a homogeneous arterial coverage. A fluorinated polymer and iVascular's TransferWise nanotechnology allow for high rates of endothelialization.